Atlas One · Human · Cellular — Scale 04

Smooth Muscle Cell

Involuntary, non-striated, mononucleated contractile cells lining blood vessels, airways, GI tract, bladder, and uterus — governing vascular resistance and airway calibre through a Ca²⁺-calmodulin-MLCK axis amplified by Rho kinase Ca²⁺ sensitisation.

CL:0000192 · Phenotypic plasticity from contractile to synthetic underlies atherosclerosis, PAH, and restenosis. Relaxation by NO/cGMP/PKG. CCBs target Cav1.2 on VSMCs to reduce blood pressure.

20–500 µmLength Range
~50%Plaque Cells from SMC
2Phenotypes (contractile / synthetic)
NO/cGMPPrimary Vasodilator Signal
CL:0000192 · Atlas One / Scale 04 — Cellular

Smooth Muscle Cell

Involuntary, non-striated, mononucleated cells in the tunica media of blood vessels, muscularis of airways and GI tract, bladder detrusor, and uterine myometrium. Contraction via Ca²⁺-calmodulin-MLCK pathway and Rho kinase (ROCK) Ca²⁺ sensitisation; relaxation by NO/cGMP/PKG. Phenotype switching from contractile (αSMA+, MYH11+) to synthetic (collagen-producing, migratory) is the cellular mechanism of atherosclerosis, PAH, and neointimal hyperplasia after stenting.

Overview

Smooth muscle cells (SMCs) are involuntary, non-striated, mononucleated cells that constitute the contractile layer of hollow visceral organs and blood vessels throughout the body. Unlike skeletal and cardiac muscle, smooth muscle lacks sarcomeric organisation and troponin-based regulation; instead, contraction is governed by calcium-calmodulin activation of myosin light chain kinase (MLCK) and amplified by the Rho kinase (ROCK) pathway. SMCs respond to autonomic neural input, circulating hormones, local paracrine mediators (NO, ET-1, Ang II), and mechanical stretch.

Vascular SMCs (VSMCs) are of particular clinical relevance: their contractile state determines peripheral vascular resistance and systemic blood pressure, and their capacity for phenotypic switching — from a quiescent contractile phenotype to a migratory, proliferative, collagen-producing synthetic phenotype — is a necessary event in atherosclerotic plaque formation, pulmonary arterial hypertension (PAH), and in-stent restenosis after coronary interventions.

Structure

Morphology: SMCs are spindle-shaped with tapered ends, 20–500 µm in length (smallest in arterioles, largest in pregnant uterus) and 5–10 µm in diameter. The single, central, elongated nucleus becomes corkscrew-shaped on contraction — a distinguishing histological feature. The cytoplasm contains abundant thin and thick filaments without regular Z-line alignment.

Contractile apparatus: Thin filaments are composed of α-smooth muscle actin (αSMA, ACTA2) and tropomyosin (without troponin — the key difference from striated muscle). Thick filaments: smooth muscle myosin II (SMMHC, MYH11). Instead of sarcomeres, SMCs organise filaments around dense bodies (cytoplasmic; α-actinin anchors) and dense plaques (membrane; vinculin, talin, integrins — anchor to ECM and transmit force).

Ca²⁺ handling: Sarcoplasmic reticulum (SR) contains IP₃R and RyR for Ca²⁺ release. Plasma membrane: L-type Cav1.2 (primary channel, CCB target), TRPC receptor-operated channels, STIM1/Orai1 store-operated channels. Ca²⁺ removal: SERCA2b (SR reuptake), PMCA (plasma membrane). Gap junctions (connexin 43, 40) electrically couple adjacent SMCs in the vascular wall.

Function — Contraction / Relaxation Circuit

  ── CONTRACTION PATHWAY ────────────────────────────────────
  Stimulus: ET-1 (ETA/Gq), Ang II (AT1R/Gq), NE (alpha1R/Gq),
            5-HT (5HT2A/Gq), TXA2 (TP/Gq), membrane stretch
       |
       v  Gq --> PLC --> IP3 + DAG
  IP3 --> SR Ca2+ release
  Depolarisation --> Cav1.2 opening --> Ca2+ entry
  [Ca2+]i rises ~100 nM --> 600-1000 nM
       |
       v  Ca2+ binds Calmodulin (4:1 complex)
  Ca2+-CaM --> binds and activates MLCK
       |
       v  MLCK phospho MLC20 (Ser19; secondarily Thr18)
  Myosin ATPase activation --> cross-bridge cycling --> FORCE

  ROCK PATHWAY (Ca2+ sensitisation):
  ET-1/Ang II --> Galpha12/13 --> RhoGEF --> RhoA-GTP --> ROCK1/ROCK2
  ROCK phospho MYPT1 (myosin phosphatase targeting subunit 1)
       --> INHIBITS MLCP (myosin light chain phosphatase)
       --> sustained MLC20 phosphorylation at SAME [Ca2+]
       ** Ca2+ sensitisation -- more force for less Ca2+ **

  ── RELAXATION PATHWAY ────────────────────────────────────
  Source: eNOS-derived NO from adjacent endothelial cells
       |
       v  NO binds soluble guanylyl cyclase (sGC, haem-Fe2+)
  GTP --> cGMP
       |
       v  PKG (protein kinase G):
    [a] Phospho MYPT1 Ser695 --> MLCP activation --> MLC dephosphorylation
    [b] Phospho BKCa (large-conductance K+ channel) --> hyperpolarisation
                                   --> Cav1.2 closing --> Ca2+ fall
    [c] Phospho MLCK Ser512 --> reduces MLCK affinity for Ca2+-CaM
  NET: cross-bridge detachment --> RELAXATION

  PHARMACOLOGICAL RELAXATION:
  CCBs (amlodipine, nifedipine) --> block Cav1.2 --> Ca2+ fall
  Nitrates (GTN, isosorbide) --> NO donor --> sGC --> cGMP
  PDE5 inhibitors (sildenafil, tadalafil) --> cGMP breakdown -->
       cGMP maintained --> PKG --> SMC relaxation (PAH + pulmonary vasodilation)
  beta2-AR agonists (salbutamol) --> Gs --> cAMP --> PKA --> MLCK inhibition
       --> bronchodilation in airway SMC

  VASOCONSTRICTORS SUMMARY:
  NE (alpha1R/Gq), Ang II (AT1R/Gq), ET-1 (ETA/Gq),
  Serotonin (5HT2A/Gq), TXA2 (TP/Gq), Neuropeptide Y (Y1/Gq)

  VASODILATORS SUMMARY:
  NO (sGC/cGMP/PKG), PGI2 (IP/Gs/cAMP/PKA), Adenosine (A2A/Gs),
  ANP (GC-A/cGMP), beta2-AR (Gs/cAMP), EDHF (K+ channel hyperpolarisation)

Phenotypic Switching

Contractile / Quiescent Phenotype

Normal adult vascular phenotype. Low proliferation, low migration. High expression: αSMA (ACTA2), SMMHC (MYH11), calponin (CNN1), SM22α (TAGLN). Maintained by myocardin + SRF transcription factor complex driving CArG-box gene expression. KLF4 low.

Synthetic / Proliferative Phenotype

↓Contractile markers; ↑collagen/ECM synthesis, ↑PDGFR-β, ↑migration, ↑proliferation. Driven by PDGF-BB, oxidised LDL, Ang II, TGF-β, inflammatory cytokines. KLF4 upregulation represses myocardin. Reversible in early disease; sustained in advanced pathology.

Foam Cell Differentiation

In atherosclerosis, synthetic SMCs can engulf modified LDL via macropinocytosis → lipid-laden SMC "foam cells." SMC-derived foam cells comprise ~50% of cells in advanced human coronary plaques (not exclusively macrophage as once thought). Identified by ACTA2-lineage tracing.

Calcification

Synthetic VSMCs may undergo osteoblastic transdifferentiation: Runx2/Osterix upregulation → matrix vesicle-mediated calcification. Major feature of medial arterial calcification (Mönckeberg sclerosis) in diabetes and CKD. ↓Vascular compliance → ↑pulse wave velocity → ↑CV mortality.

Pathology

Atherosclerosis — SMC Contribution

Endothelial injury signals (oxLDL, Ang II, PDGF-BB) → VSMC phenotypic switch (contractile → synthetic; KLF4 upregulation, myocardin downregulation) → intimal migration, proliferation, collagen secretion → fibrous cap formation. SMC-derived foam cells (~50% of advanced plaque cells) contribute to lipid core. Cap thinning by SMC apoptosis (TNF-α, IFN-γ, excessive ROS) + MMP-mediated collagen degradation (from macrophages) → plaque vulnerability → rupture → acute MI/stroke.

Pulmonary Arterial Hypertension (PAH)

BMPR2 loss-of-function (heritable PAH, ~80% of HPAH, ~25% of IPAH) → unchecked VSMC proliferation and hypertrophy in pulmonary arterioles (medial hyperplasia) + endothelial dysfunction (angioproliferative lesions) + perivascular inflammation → progressive obliterative arteriopathy → ↑PVR → right ventricular pressure overload → RV failure. Treatment: ERA (bosentan, ambrisentan — ET-1 block), PDE5i (sildenafil, tadalafil — ↑cGMP), prostacyclin analogues (epoprostenol — IP/cAMP), riociguat (sGC stimulator).

Coronary Artery Spasm (Prinzmetal Angina)

ROCK hyperactivation in coronary artery SMCs → MLC₂₀ phosphorylation without ↑[Ca²⁺]i → coronary vasospasm → ST-elevation angina at rest, often in young individuals without obstructive disease. Trigger: hyperventilation, cold, acetylcholine provocation test. Treatment: CCBs (diltiazem, verapamil) or long-acting nitrates. Fasudil (ROCK inhibitor) effective in Japan/China; not approved in Western markets.

Bronchospasm and Asthma

Allergen → IgE/FcεRI → mast cell degranulation → histamine, LTD₄, PGD₂ → airway SMC contraction → bronchoconstriction. Chronic inflammation → airway SMC hypertrophy and hyperplasia (via TGF-β, PDGF) → airway remodelling → fixed airflow limitation. Mast cells adhere directly to airway SMCs in asthma (through SCF/c-Kit and CXCL10 axes). Treatment: β₂-agonists (salbutamol, salmeterol → cAMP → PKA → MLCK inhibition); anticholinergics (ipratropium → block M₃R-driven contraction); ICS (beclomethasone → ↓inflammatory mediators); dupilumab (anti-IL-4Rα) for severe eosinophilic asthma.

Leiomyoma and Leiomyosarcoma

Leiomyoma (uterine fibroid): Benign SMC tumour; most common tumour in women of reproductive age (prevalence up to 70%). Oestrogen/progesterone-dependent; MED12 exon 1/2 somatic mutations in ~70%. Symptoms: menorrhagia, pelvic pressure, infertility. Treatment: GnRH analogues (medical regression), UAE (uterine artery embolisation), myomectomy/hysterectomy. Leiomyosarcoma: Malignant SMC tumour; uterus, retroperitoneum, GI tract; TP53, RB1, PTEN mutations; aggressive — doxorubicin-based chemotherapy, poor prognosis.

Cross-Atlas Connections

Part ofCardiovascular System (tunica media) Crosstalk withEndothelial Cell (NO, ET-1, PGI₂) Modulated byCalcium Channel Blockers Modulated byNitrates / PDE5 Inhibitors Phenotype overlapMyofibroblast (αSMA) Part ofRespiratory System (airway)

References